Coenzyme Q10 in the Treatment of Mitochondrial Disease
Autor(a) principal: | |
---|---|
Data de Publicação: | 2017 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Journal of Inborn Errors of Metabolism and Screening |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2326-45942017000100801 |
Resumo: | Abstract Currently, there is a paucity of available treatment strategies for oxidative phosphorylation disorders. Coenzyme Q10 (CoQ10) and related synthetic quinones are the only agents to date that have proven to be beneficial in the treatment of these heterogeneous disorders. The therapeutic efficacy of CoQ10 is not restricted to patients with an underlying CoQ10 deficiency and is thought to result from its ability to restore electron flow in the mitochondrial respiratory chain (MRC) as well as to increase the cellular antioxidant capacity. At present, however, there is no consensus on the appropriate dosage or therapeutic plasma level of CoQ10, and this information will be required before CoQ10 can be utilized effectively in the treatment of mitochondrial disease. The following review will outline our current knowledge on the use of CoQ10 in the treatment of MRC disorders and primary CoQ10 deficiencies. |
id |
IGPT-1_c668e56d73c6bc5b2e24180d10edc0f0 |
---|---|
oai_identifier_str |
oai:scielo:S2326-45942017000100801 |
network_acronym_str |
IGPT-1 |
network_name_str |
Journal of Inborn Errors of Metabolism and Screening |
repository_id_str |
|
spelling |
Coenzyme Q10 in the Treatment of Mitochondrial Diseasecoenzyme Q10mitochondrial respiratory chain (MRC)oxidative stressantioxidantAbstract Currently, there is a paucity of available treatment strategies for oxidative phosphorylation disorders. Coenzyme Q10 (CoQ10) and related synthetic quinones are the only agents to date that have proven to be beneficial in the treatment of these heterogeneous disorders. The therapeutic efficacy of CoQ10 is not restricted to patients with an underlying CoQ10 deficiency and is thought to result from its ability to restore electron flow in the mitochondrial respiratory chain (MRC) as well as to increase the cellular antioxidant capacity. At present, however, there is no consensus on the appropriate dosage or therapeutic plasma level of CoQ10, and this information will be required before CoQ10 can be utilized effectively in the treatment of mitochondrial disease. The following review will outline our current knowledge on the use of CoQ10 in the treatment of MRC disorders and primary CoQ10 deficiencies.Latin American Society Inborn Errors and Neonatal Screening (SLEIMPN); Instituto Genética para Todos (IGPT)2017-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S2326-45942017000100801Journal of Inborn Errors of Metabolism and Screening v.5 2017reponame:Journal of Inborn Errors of Metabolism and Screeninginstname:Instituto Genética para Todos (IGPT)instacron:IGPT10.1177/2326409817707771info:eu-repo/semantics/openAccessNeergheen,VirunaChalasani,AnnapurnaWainwright,LukeYubero,DeliaMontero,RaquelArtuch,RafaelHargreaves,Iaineng2019-05-14T00:00:00Zoai:scielo:S2326-45942017000100801Revistahttp://jiems-journal.org/ONGhttps://old.scielo.br/oai/scielo-oai.phpjiems@jiems-journal.org||rgiugliani@hcpa.edu.br2326-45942326-4594opendoar:2019-05-14T00:00Journal of Inborn Errors of Metabolism and Screening - Instituto Genética para Todos (IGPT)false |
dc.title.none.fl_str_mv |
Coenzyme Q10 in the Treatment of Mitochondrial Disease |
title |
Coenzyme Q10 in the Treatment of Mitochondrial Disease |
spellingShingle |
Coenzyme Q10 in the Treatment of Mitochondrial Disease Neergheen,Viruna coenzyme Q10 mitochondrial respiratory chain (MRC) oxidative stress antioxidant |
title_short |
Coenzyme Q10 in the Treatment of Mitochondrial Disease |
title_full |
Coenzyme Q10 in the Treatment of Mitochondrial Disease |
title_fullStr |
Coenzyme Q10 in the Treatment of Mitochondrial Disease |
title_full_unstemmed |
Coenzyme Q10 in the Treatment of Mitochondrial Disease |
title_sort |
Coenzyme Q10 in the Treatment of Mitochondrial Disease |
author |
Neergheen,Viruna |
author_facet |
Neergheen,Viruna Chalasani,Annapurna Wainwright,Luke Yubero,Delia Montero,Raquel Artuch,Rafael Hargreaves,Iain |
author_role |
author |
author2 |
Chalasani,Annapurna Wainwright,Luke Yubero,Delia Montero,Raquel Artuch,Rafael Hargreaves,Iain |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Neergheen,Viruna Chalasani,Annapurna Wainwright,Luke Yubero,Delia Montero,Raquel Artuch,Rafael Hargreaves,Iain |
dc.subject.por.fl_str_mv |
coenzyme Q10 mitochondrial respiratory chain (MRC) oxidative stress antioxidant |
topic |
coenzyme Q10 mitochondrial respiratory chain (MRC) oxidative stress antioxidant |
description |
Abstract Currently, there is a paucity of available treatment strategies for oxidative phosphorylation disorders. Coenzyme Q10 (CoQ10) and related synthetic quinones are the only agents to date that have proven to be beneficial in the treatment of these heterogeneous disorders. The therapeutic efficacy of CoQ10 is not restricted to patients with an underlying CoQ10 deficiency and is thought to result from its ability to restore electron flow in the mitochondrial respiratory chain (MRC) as well as to increase the cellular antioxidant capacity. At present, however, there is no consensus on the appropriate dosage or therapeutic plasma level of CoQ10, and this information will be required before CoQ10 can be utilized effectively in the treatment of mitochondrial disease. The following review will outline our current knowledge on the use of CoQ10 in the treatment of MRC disorders and primary CoQ10 deficiencies. |
publishDate |
2017 |
dc.date.none.fl_str_mv |
2017-01-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2326-45942017000100801 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2326-45942017000100801 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1177/2326409817707771 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Latin American Society Inborn Errors and Neonatal Screening (SLEIMPN); Instituto Genética para Todos (IGPT) |
publisher.none.fl_str_mv |
Latin American Society Inborn Errors and Neonatal Screening (SLEIMPN); Instituto Genética para Todos (IGPT) |
dc.source.none.fl_str_mv |
Journal of Inborn Errors of Metabolism and Screening v.5 2017 reponame:Journal of Inborn Errors of Metabolism and Screening instname:Instituto Genética para Todos (IGPT) instacron:IGPT |
instname_str |
Instituto Genética para Todos (IGPT) |
instacron_str |
IGPT |
institution |
IGPT |
reponame_str |
Journal of Inborn Errors of Metabolism and Screening |
collection |
Journal of Inborn Errors of Metabolism and Screening |
repository.name.fl_str_mv |
Journal of Inborn Errors of Metabolism and Screening - Instituto Genética para Todos (IGPT) |
repository.mail.fl_str_mv |
jiems@jiems-journal.org||rgiugliani@hcpa.edu.br |
_version_ |
1754732520001241088 |